Article
Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea.
Cancer medicine - 1 Sept 2021
Kim Taeyun, Jang Tae Won, Choi Chang Min, Kim Mi-Hyun, Lee Sung Yong, Park Cheol-Kyu, Chang Yoon Soo, Lee Kye Young, Kim Seung Joon, Yang Sei Hoon, Ryu Jeong Seon, Lee Jeong Eun, Lee Shin Yup, Park Chan Kwon, Lee Sang Hoon, Jang Seung Hun, Yoon Seong Hoon
Abstract excerpt
OBJECTIVES: The optimal sequence for the administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for treating non-small cell lung cancer (NSCLC) is still unclear. This study aimed to evaluate the efficacy of sequential afatinib and osimertinib treatment in patients with NSCLC harboring EGFR mutations. MATERIALS AND METHODS: Electronic records of patients with EGFR-mutated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.